Sagefield Capital’s Astria Therapeutics ATXS Stock Holding History

Sagefield Capital’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-39,576	Closed	-$518K	–	114
2025 Q4	$518K	Buy	+39,576	New	+$473K	0.04%	101

Sagefield Capital's ATXS Position: Q1 2026 in Review

Sagefield Capital sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 39,576 shares — an estimated $518K sold.

Sagefield Capital first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $518K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Sagefield Capital reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Sagefield Capital sold 39,576 Astria Therapeutics shares in Q1 2026, an estimated $518K.
Sagefield Capital first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Sagefield Capital's Astria Therapeutics position peaked at $518K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Sagefield Capital's 13F filing for Q1 2026, filed 15 May 2026.